Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HBB | P68871 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996435 | 0.83 | CRBN (0.42) | CRBNTSHRALDH1A1MAPTALOX15 | |
| SCHEMBL19359372 | 0.77 | CRBN (0.73) | CRBNTSHRALDH1A1DDB1BRD4 | |
| SCHEMBL4081888 | 0.75 | CRBN (0.58) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL1499656 | 0.73 | CRBN (1.00) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL6180704 | 0.73 | CRBN (1.00) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL29943635 | 0.73 | CRBN (1.00) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL6178113 | 0.73 | CRBN (1.00) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL9631384 | 0.73 | CRBN (0.67) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL25834145 | 0.71 | CRBN (0.72) | CRBNTSHRALDH1A1DDB1CHRM2 | |
| SCHEMBL5435284 | 0.71 | CRBN (0.72) | CRBNTSHRALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220026439-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV (BE) | 2022-01-27 | — | — | US | disclosed |
| EP-3899539-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3755718-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200399386-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2020-12-24 | — | — | US | disclosed |
| WO-2019164891-A9 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020132189-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | ORIONIS BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019164891-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| US-9857359-B2 | Methods for determining drug efficacy using cereblon-associated proteins | CELGENE CORPORATION (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160153998-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORP (US) | 2016-06-02 | — | — | US | disclosed |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION | 2015-06-04 | — | — | US | disclosed |
| US-20140162282-A1 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS | CELGENE CORPORATION (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014028445-A2 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20110280849-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | ANTHROGENESIS CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100098657-A1 | Method of Treating Cancer with Immunomodulatory Compounds and IgG | CELGENE CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20090148853-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399386-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | CRBN 401/4885TSHR 2971/4885ALDH1A1 3352/4885 |
| US-20110280849-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | PGF, PBK, NFATC1 | CRBN 969/4885TSHR 3767/4885ALDH1A1 1636/4885 |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885TSHR 2988/4885ALDH1A1 1870/4885 |
| US-20100098657-A1 | Method of Treating Cancer with Immunomodulatory Compounds and IgG | IL2, FCGR3B, FCGR1A | CRBN 991/4885TSHR 2405/4885ALDH1A1 2403/4885 |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885TSHR 2988/4885ALDH1A1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.